Amylyx Pharmaceuticals Inc (AMLX)
Healthcare
Drug Manufacturers - Specialty & Generic
20.30 $
-2.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Amylyx Pharmaceuticals Inc (AMLX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -123 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -11 | -37 | -75 | -180 | 12 | -168 | -123 | |
| 0.0 | 0.0 | 0.1 | 0.5 | 1.1 | 0.9 | 0.5 | |
| 0.1 | 0.2 | 3.1 | 22 | 37 | 33 | 28 | |
| -0.5 | 3.0 | 8.5 | 22 | – | – | – | |
| 3.5 | 2.6 | 4.6 | -1.6 | -66 | -46 | -1.1 | |
| 0.2 | 0.2 | 0.4 | 2.5 | 1.2 | 0.2 | 0.1 | |
| -0.2 | -0.2 | -46 | -239 | 92 | 76 | 14 | |
| – | – | – | 435 | -3.3 | – | – | |
| 0.6 | 17 | 26 | 0.0 | 0.0 | – | – | |
| 0.7 | 47 | 159 | 432 | 3.5 | 0.3 | 257 | |
| 3.1 | 10.0 | 37 | 13 | 108 | -92 | 149 | |
| -11 | -37 | -75 | -182 | 11 | -168 | -123 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.